Welcome to our dedicated page for Cyclacel Pharmaceuticals news (Ticker: CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharmaceuticals stock.
Cyclacel Pharmaceuticals, Inc (symbol: CYCC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative targeted therapies for cancer and other proliferative diseases. Headquartered in London, United Kingdom, Cyclacel is at the forefront of creating novel drugs that target the cell cycle, specifically through CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors.
The company's pipeline includes several promising candidates:
- Fadraciclib: A CDK2/9 inhibitor, fadraciclib is in development for the treatment of solid tumors and lymphoma. Recent data supports its ongoing development, showcasing its potential as a crucial therapy for these conditions.
- Sapacitabine: An oral nucleoside analogue, sapacitabine is being developed for the treatment of acute myeloid leukemia (AML) and other hematologic malignancies.
- Plogosertib: A PLK1 inhibitor, plogosertib is being studied for its efficacy in treating various cancers.
Cyclacel's approach to drug development is underscored by its focus on the cell cycle, which is a fundamental process that cells go through as they grow and divide. By targeting specific phases of the cell cycle, Cyclacel aims to disrupt the proliferation of cancer cells, thereby offering new treatment options for patients with limited alternatives.
The financial condition of Cyclacel Pharmaceuticals is reflective of a typical clinical-stage company, with significant investment in research and development activities. The company continues to seek partnerships and collaborations to advance its drug candidates through clinical trials and regulatory approval processes.
With a robust pipeline and a strategic focus on cell cycle inhibitors, Cyclacel Pharmaceuticals is making significant strides in the biopharmaceutical industry. Investors and stakeholders should keep an eye on Cyclacel’s progress as it continues to achieve milestones and contribute to the development of breakthrough cancer therapies.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company focused on developing innovative cancer medicines, has announced it will release its second quarter 2024 financial results on Wednesday, August 14, 2024. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day to discuss the results.
Investors and interested parties can access the conference call by dialing (800) 225-9448 (US) or (203) 518-9708 (international). The live webcast will be available on the Corporate Presentations page of Cyclacel's website. An audio replay will be accessible for 7 days, while the webcast will be archived for 90 days.
Cyclacel Pharmaceuticals announced it received a notice from the European Patent Office intending to grant a new patent for plogosertib pharmaceutical compositions. This patent will extend the exclusivity of plogosertib, a PLK1 inhibitor, until August 2040, excluding any extensions. The patent strengthens Cyclacel’s portfolio and supports a new oral formulation of plogosertib with improved bioavailability. Cyclacel aims to evaluate plogosertib for ARID1A- and/or SMARCA-mutated cancers. Additionally, its lead drug candidate, fadraciclib, is undergoing a proof-of-concept study in patients with solid tumors and T-cell lymphoma, with initial data expected in the second half of 2024.
Cyclacel Pharmaceuticals announced preclinical data for fadraciclib, a CDK2/9 inhibitor, demonstrating efficacy in metastatic colorectal cancer (CRC) models. Presented at the 2024 ASCO Annual Meeting, the study showed that fadraciclib significantly inhibited tumor growth, induced apoptosis, and triggered anaphase catastrophe in CRC patient-derived organoids (PDOs) and xenografts (PDXs). The research highlighted fadraciclib's superiority over standard chemotherapy and palbociclib in CRC models. Cyclacel's CEO, Spiro Rombotis, emphasized fadraciclib’s broad potential in multiple tumor types. Initial proof of concept data is expected in the second half of 2024.
Cyclacel Pharmaceuticals presented new clinical data on their CDK2/9 inhibitor, fadraciclib, at the 2024 ASCO Annual Meeting. The Phase 1 study, CYC065-101, involved heavily pretreated patients with various cancers, demonstrating clinical benefits in endometrial, lung, ovarian, pancreatic cancers, and T-cell lymphoma. Fadraciclib showed good tolerance with the most common adverse events being nausea, vomiting, and diarrhea. Pharmacokinetic (PK) and pharmacodynamic (PD) data indicated dose proportionality and efficacy in CDKN2A/B suppression. The Phase 2 proof of concept part is currently enrolling patients with CDKN2A/B loss or T-cell lymphoma, with initial results expected in the second half of 2024.
Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported its first quarter 2024 financial results and provided a business update. Key highlights include enrolling patients in the Phase 2 proof-of-concept (PoC) study of oral fadraciclib, a CDK2/9 inhibitor, with data to be presented at the ASCO Annual Meeting. The company received $8.0 million from a private placement, bolstering its balance sheet. As of March 31, 2024, Cyclacel had $9.9 million in pro forma cash and cash equivalents, including $0.8 million from the UK R&D tax credit. The net loss for Q1 2024 was $2.9 million, a decrease from $5.8 million in Q1 2023. R&D expenses were $2.8 million compared to $5.7 million last year. The company plans to report key data from its ongoing clinical trials later this year.
Cyclacel Pharmaceuticals, Inc. will release its first quarter 2024 financial results on May 14, 2024. The company focuses on developing innovative cancer treatments and will host a conference call and webcast to discuss the results.
Cyclacel Pharmaceuticals, a biopharmaceutical company, closed an $8.0 million private placement under NASDAQ rules, offering shares of common stock, series A warrants, and short-term series B warrants. The gross proceeds were $8.0 million, with H.C. Wainwright & Co. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
Cyclacel Pharmaceuticals, Inc. announced an $8.0 million private placement under Nasdaq rules, offering shares of common stock and warrants to purchase more shares at a fixed price. The placement is expected to close on May 2, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
FAQ
What is the current stock price of Cyclacel Pharmaceuticals (CYCC)?
What is the market cap of Cyclacel Pharmaceuticals (CYCC)?
What does Cyclacel Pharmaceuticals specialize in?
Where is Cyclacel Pharmaceuticals headquartered?
What are the key drug candidates in Cyclacel's pipeline?
What is fadraciclib?
What recent achievements has Cyclacel made?
What type of company is Cyclacel Pharmaceuticals?
What is sapacitabine?
What is plogosertib?
What is the significance of cell cycle inhibitors in cancer treatment?
How can investors stay updated on Cyclacel's progress?
